The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 07, 2006
Filed:
Mar. 30, 2004
José L. Boyer, Chapel Hill, NC (US);
James G. Douglass, Iii, Apex, NC (US);
Sammy R. Shaver, Chapel Hill, NC (US);
Krzysztof Bednarski, Raleigh, NC (US);
Benjamin R. Yerxa, Raleigh, NC (US);
Gillian M. Olins, San Diego, CA (US);
José L. Boyer, Chapel Hill, NC (US);
James G. Douglass, III, Apex, NC (US);
Sammy R. Shaver, Chapel Hill, NC (US);
Krzysztof Bednarski, Raleigh, NC (US);
Benjamin R. Yerxa, Raleigh, NC (US);
Gillian M. Olins, San Diego, CA (US);
Inspire Pharmaceuticals, Inc., Durham, NC (US);
University of North Carolina, Chapel Hill, NC (US);
Abstract
This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis. The method comprises administering to a subject a pharmaceutical composition comprising a therapeutic effective amount of P2Yreceptor antagonist compound, wherein said amount is effective to bind the P2Yreceptors on platelets and inhibit ADP-induced platelet aggregation. The P2Yreceptor antagonist compounds useful for this invention include mononucleoside 5'-monophosphates, mononucleoside polyphosphates, and dinucleoside polyphosphates of general Formula I, or salts thereof. The present invention also provides novel compounds of mononucleoside 5′-monophosphates, mononucleoside polyphosphates, and dinucleoside polyphosphates. The present invention further provides pharmaceutical formulations comprising mononucleoside 5′-monophosphates, mononucleoside polyphosphates, or dinucleoside polyphosphates.